Isomorphic Labs Raises $5B Series C | 2.4x Its $2.1B May Round

Isomorphic Labs raised a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining, to push its AI-designed drug candidates toward clinical trials; the company did not disclose its valuation.

By the Numbers

$5B
Isomorphic Labs Series C, Nov 2026
$2.1B
Isomorphic Labs Series B, May 2026
About 2.4x
Series C vs Series B size
2021
Isomorphic Labs founded (DeepMind spinout)
$50B (not confirmed)
Valuation reported sought (Bloomberg)
Trace Cohen
By Trace Cohen · Value Add Pulse Funding Desk
Founder & Editor-in-chief, Value Add VC
3 min read
Isomorphic Labs Raises $5B Series C | 2.4x Its $2.1B May Round: key figures
ShareXLinkedInEmail

THE RUNDOWN

1

Isomorphic Labs' $5B Series C is more than double the $2.1B Series B it announced on May 12, 2026, raised in about six months

2

Sequoia Capital and Greenoaks co-led and Andreessen Horowitz joined as a new investor, putting three of the largest growth checkbooks behind one AI drug lab

3

The money is meant to move drug candidates from preclinical work into human clinical trials, the step where AI drug design has to prove itself

4

The valuation was not disclosed; Bloomberg had reported earlier in November that the company sought a $50B mark, which remains unconfirmed

The VC Read

Value Add VC analysis

This is a growth round priced like a platform, written before a single patient has been dosed. Sequoia and Greenoaks are underwriting the engine, not a molecule, so the diligence item is how many wholly owned programs Iso keeps versus how much upside it gave Lilly, Novartis and J&J. If the first trial filing slips, the $50B number Bloomberg floated becomes the ceiling, not the floor.

Analysis

As of November 17, 2026, Isomorphic Labs has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, TechCrunch reported. Andreessen Horowitz joined as a new investor, and the company said the money will help take its drug candidates into clinical trials. Isomorphic Labs did not disclose its new valuation.

The round lands roughly six months after Isomorphic Labs' $2.1 billion Series B, which makes the Series C about 2.4 times the size of the previous raise. That is a comparison of capital raised, not of valuation: neither round's price has been published by the company.

What does Isomorphic Labs do?

Isomorphic Labs was spun out of Google DeepMind in 2021, and its own site says the AlphaFold breakthrough "inspired Sir Demis Hassabis to found Iso in 2021" (Isomorphic Labs). Hassabis is founder and CEO. TechCrunch reported that he stepped back from leading DeepMind to focus on drug discovery and became its chairman.

“The round lands roughly six months after Isomorphic Labs' $2.1 billion Series B, which makes the Series C about 2.4 times the size of the previous raise.”

The product is a drug-design engine that TechCrunch describes as using "a slew of simulation AI models" to design molecules. The company calls it IsoDDE in its Series B announcement. Isomorphic Labs has signed deals with Eli Lilly, Novartis and Johnson & Johnson, according to TechCrunch, though none of those deal values were stated in the coverage we opened. Per TechCrunch, the company has reported positive preclinical results in oncology and immunology. It has not yet put a drug into human trials, which is what this round is for.

How much has Isomorphic Labs raised?

The two rounds that the company itself has announced in 2026 total $7.1 billion: the $2.1 billion Series B and this $5 billion Series C.

The Series B was led by Thrive Capital, with existing backers Alphabet and GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund, per Isomorphic Labs' Series B announcement dated May 12, 2026.

Value Add VC data

  • May 2026, Series B -- $2.1B at an undisclosed valuation, led by Thrive Capital (source)
  • Nov 2026, Series C -- $5B at an undisclosed valuation, co-led by Greenoaks and Sequoia Capital (source)

No multiple of the prior mark is possible, because neither valuation is public. Bloomberg reported earlier this month that the company was seeking funding at a $50 billion valuation, as TechCrunch noted; that figure is a reported target, not a confirmed price. For scale, two rounds from the same day are each a tenth of Isomorphic's raise or less:

Who invested in Isomorphic Labs?

Greenoaks and Sequoia Capital co-led the Series C, with Andreessen Horowitz new to the cap table. Existing backers also wrote checks, including Alphabet's GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund, per TechCrunch. TechCrunch names GV, CapitalG, Thrive, MGX, Temasek and the UK Sovereign AI Fund among the existing backers that invested again. Thrive led the May round but not this one.

AI drug discovery: what the headline misses

The bear case is the gap between capital and evidence. Isomorphic Labs now has $7.1 billion of announced 2026 funding and no disclosed human data. Preclinical results in oncology and immunology are early; human trials are where candidates get tested on safety and efficacy, and AI design does not skip them. The pharma partnerships help, but their economics were not disclosed, so outsiders cannot tell how much of the company's value rests on milestone payments versus wholly owned programs.

The comparison to the rest of biotech on this page is telling. Johnson & Johnson agreed to pay $2.2 billion upfront for Ollin Biosciences, a clinical-stage company. Isomorphic Labs raised more than twice that amount in one private round before reaching the clinic. The next date that matters is its first trial filing: until a drug designed by IsoDDE doses a patient, the $5 billion is a bet on Hassabis and AlphaFold, not on a product.

ShareXLinkedInEmail

More from the Pulse archive: Startup & VC Funding coverage → · All topics

Key Sources

1 source

Reported by TechCrunch · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with The VC Read, a few times a week. Free to subscribe, no spam.

No spam, unsubscribe anytime. Sent via Substack · Privacy · or subscribe on Substack ↗